Decreased expression of SATB2: A novel independent prognostic marker of worse outcome in laryngeal carcinoma patients

Tian Run Liu, Li Hua Xu, An Kui Yang, Qian Zhong, Ming Song, Man Zhi Li, Li Juan Hu, Fu Jin Chen, Ze Dong Hu, Ping Han, Mu Sheng Zeng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC. Methods: The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells. Results: The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery. Conclusions: SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.

Original languageEnglish (US)
Article numbere40704
JournalPloS one
Volume7
Issue number7
DOIs
StatePublished - Jul 16 2012

Fingerprint

AT Rich Sequence
carcinoma
binding proteins
Carrier Proteins
Carcinoma
squamous cell carcinoma
Squamous Cell Carcinoma
Tumors
neoplasms
Tissue
Assays
Neoplasms
cells
assays
Survival
Cell proliferation
Cell growth

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Decreased expression of SATB2 : A novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. / Liu, Tian Run; Xu, Li Hua; Yang, An Kui; Zhong, Qian; Song, Ming; Li, Man Zhi; Hu, Li Juan; Chen, Fu Jin; Hu, Ze Dong; Han, Ping; Zeng, Mu Sheng.

In: PloS one, Vol. 7, No. 7, e40704, 16.07.2012.

Research output: Contribution to journalArticle

Liu, Tian Run ; Xu, Li Hua ; Yang, An Kui ; Zhong, Qian ; Song, Ming ; Li, Man Zhi ; Hu, Li Juan ; Chen, Fu Jin ; Hu, Ze Dong ; Han, Ping ; Zeng, Mu Sheng. / Decreased expression of SATB2 : A novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. In: PloS one. 2012 ; Vol. 7, No. 7.
@article{cbfc8fb6f1394f1eba3b605c8b4c5e1b,
title = "Decreased expression of SATB2: A novel independent prognostic marker of worse outcome in laryngeal carcinoma patients",
abstract = "Background: To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC. Methods: The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells. Results: The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery. Conclusions: SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.",
author = "Liu, {Tian Run} and Xu, {Li Hua} and Yang, {An Kui} and Qian Zhong and Ming Song and Li, {Man Zhi} and Hu, {Li Juan} and Chen, {Fu Jin} and Hu, {Ze Dong} and Ping Han and Zeng, {Mu Sheng}",
year = "2012",
month = "7",
day = "16",
doi = "10.1371/journal.pone.0040704",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Decreased expression of SATB2

T2 - A novel independent prognostic marker of worse outcome in laryngeal carcinoma patients

AU - Liu, Tian Run

AU - Xu, Li Hua

AU - Yang, An Kui

AU - Zhong, Qian

AU - Song, Ming

AU - Li, Man Zhi

AU - Hu, Li Juan

AU - Chen, Fu Jin

AU - Hu, Ze Dong

AU - Han, Ping

AU - Zeng, Mu Sheng

PY - 2012/7/16

Y1 - 2012/7/16

N2 - Background: To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC. Methods: The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells. Results: The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery. Conclusions: SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.

AB - Background: To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC. Methods: The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells. Results: The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery. Conclusions: SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84864020073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864020073&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0040704

DO - 10.1371/journal.pone.0040704

M3 - Article

C2 - 22815795

AN - SCOPUS:84864020073

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e40704

ER -